HUTCHMED (China) HMDCF
NASDAQ HMDCF
$2.16 +0.00 (+0.00%)
At close: Sep 8, 2026 · 4:00 PM EDT

HUTCHMED (China) (HMDCF) Total Current Liabilities (2015 - 2026)

HUTCHMED (China)'s (HMDCF) quarterly Total Current Liabilities came in at $275.2 million in Q2 2026, down 19.61% year-over-year from $342.3 million in Q2 2025, and down 12.85% quarter-over-quarter from $315.8 million in Q4 2025.

Analysis

HUTCHMED (China) (HMDCF) Total Current Liabilities (2015 - 2026) Analysis & Trends

HUTCHMED (China) (HMDCF) has reported Total Current Liabilities for 12 consecutive years, with $275.2 million the latest figure, recorded in Q2 2026.

  • On a quarterly basis, Total Current Liabilities fell 19.61% year-over-year to $275.2 million in Q2 2026; TTM through Jun 2026 was $275.2 million, a 19.61% decrease from a year earlier, with the FY2025 full-year figure at $315.8 million, changed N/A from the prior year.
  • Total Current Liabilities was $275.2 million for Q2 2026 at HUTCHMED (China), down from $315.8 million in the prior quarter.
  • Over five years, Total Current Liabilities peaked at $373.3 million in Q2 2024 and troughed at $275.2 million in Q2 2026.
  • A 5-year average of $331.9 million and a median of $340.9 million in 2023 frame the typical range for Total Current Liabilities.
  • Across the five-year window, Total Current Liabilities gained 29.93% in 2022 and dropped 19.61% in 2026, its largest moves.
  • Over 5 years, Total Current Liabilities stood at $353.9 million in 2022, then slipped by 3.68% to $340.9 million in 2023, then gained by 9.51% to $373.3 million in 2024, then declined by 15.41% to $315.8 million in 2025, then slipped by 12.85% to $275.2 million in 2026.
  • The last three Total Current Liabilities figures came in at $275.2 million (Q2 2026), $315.8 million (Q4 2025), and $342.3 million (Q2 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Current Liabilities (Qtr)
1 Amgen 211.51 Bn 197.52 Bn 7.24 Bn 25.50 Bn
2 Gilead Sciences 181.48 Bn 178.30 Bn 6.22 Bn 11.02 Bn
3 Vertex Pharmaceuticals 132.45 Bn 124.60 Bn 2.84 Bn 3.94 Bn
4 Regeneron Pharmaceuticals 82.87 Bn 74.88 Bn 3.93 Bn 5.53 Bn
5 Argenx Se 61.59 Bn 56.41 Bn 1.37 Bn 1.58 Bn
6 Moderna 54.72 Bn 49.59 Bn 52.00 Mn 2.53 Bn
7 Alnylam Pharmaceuticals 34.13 Bn 30.82 Bn 992.69 Mn 1.51 Bn
8 Biogen 31.29 Bn 30.01 Bn 1.96 Bn 3.92 Bn
9 Roivant Sciences 30.31 Bn 30.31 Bn 1.16 Mn 283.60 Mn
10 HUTCHMED (China) 376.85 Mn 391.04 Mn - 275.21 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 275.21 Mn
Dec 31, 2025 315.78 Mn
Jun 30, 2025 342.35 Mn
Jun 30, 2024 373.29 Mn
Jun 30, 2023 340.86 Mn
Dec 31, 2022 353.90 Mn
Jun 30, 2022 321.86 Mn
Dec 31, 2021 311.66 Mn
Jun 30, 2021 247.72 Mn
Mar 31, 2021 188.52 Mn
Dec 31, 2020 158.40 Mn
Jun 30, 2020 119.39 Mn
Dec 31, 2019 113.10 Mn
Sep 30, 2019 105.35 Mn
Jun 30, 2019 110.61 Mn
Mar 31, 2019 101.33 Mn
Dec 31, 2018 85.48 Mn
Jun 30, 2018 84.58 Mn
Dec 31, 2017 104.60 Mn
Jun 30, 2017 96.84 Mn